Pursuant to Regulations 30 & 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, IOL Chemicals And Pharmaceuticals has informed that the Board of Directors in its meeting held on 4th February 2022 has considered and approved the following: Audited Financial Results for the Quarter and Nine Months ended 31st December 2021. Copy of the said financial results along with unmodified Auditors' Report thereon is enclosed, Declared an Interim Dividend of Rs 4 per Equity Share of Face Value Rs 10 each for the Financial Year 2021-222, Fixed 16th February 2022 as the Record Date to determine the names of the equity shareholders, who shall be entitled to receive the above said Interim Dividend. The payment of the Interim Dividend shall be made to the eligible shareholders before 5th March 2022, Re-appointed Rajender Mohan Malla (00136657) as an Independent Director of the Company, for a second term of 5 years from 6th February 2022 upto 5th February 2027 subject to the requisite approval of the members of the Company and Re-appointed Harpal Singh (06658043) as an Independent Director of the Company, for a second term of 5 years from 6th February 2022 upto 5th February 2027 subject to requisite approval of the members of the Company. The company confirmed and declared that Auditors Report issued by the Statutory Auditors on the financial results of the Company for the quarter and nine months ended 31st December 2021 is an Unmodified Report. The meeting of Board of Directors commenced at 4:00 pm and concluded at 6:18 pm. The above Audited Financial Results are also available on the website of the Company: www.iolcp.com.
The above information is a part of company’s filings submitted to BSE.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1797.80 |
| Dr. Reddys Lab | 1213.90 |
| Cipla | 1486.30 |
| Lupin | 2069.95 |
| Zydus Lifesciences | 948.70 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Claim your FREE 15-day access to the most practical investing handbook.
Hurry, limited to the first 10 users today!
Become a savvy and confident
stock investor.
Don't miss out! First 10 users today get it FREE
Download APP
